Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D04NPP
|
||||
| Former ID |
DNCL001638
|
||||
| Drug Name |
SLX-2101
|
||||
| Indication | Erectile dysfunction; Hypertension; Raynaud's disease [ICD9: 302.72, 607.84, 401, 443; ICD10:F52.2, N48.4, I10-I16, I73.0] | Discontinued in Phase 2 | [1] | ||
| Company |
Kadmon Pharmaceuticals; Nano Terra
|
||||
| Target and Pathway | |||||
| Target(s) | CGMP-specific 3',5'-cyclic phosphodiesterase | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Purine metabolism | ||||
| cGMP-PKG signaling pathway | |||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
| Reactome | cGMP effects | ||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022583) | ||||
| REF 2 | Novel phosphodiesterase-5 (PDE5) inhibitors in the alleviation of erectile dysfunction due to diabetes and ageing-induced oxidative stress. Expert Opin Investig Drugs. 2008 Jun;17(6):855-64. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.